General Counsel, Chief Compliance Officer, and Secretary · CG Oncology, Inc. (CGON)

Joshua Patterson

FY2025 is the first fiscal year CompBrief holds for Joshua Patterson as a named executive officer of CG Oncology; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$2,364,380

4th of 7 named executive officers at CG Oncology by FY2025 total.

7 named officers on file for CG Oncology, FY2025

See an example →

What this number hides

The filing gives the total. CG Oncology’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Velarion Intel · free for 3 days · no card

See how CG Oncology’s whole pay program stands against its peers

  • CG Oncology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CGON→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2026 (DEF 14A).

Free

Get Joshua Patterson’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Joshua Patterson and every company like it: Velarion Intel, free for 3 days, no card →

Joshua Patterson compensation by year

CG Oncology Summary Compensation Table · the one fiscal year held
In US dollars, as CG Oncology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$461,523
Bonus$0
Stock awards$0
Option awards$1,670,561
Non-equity incentive$207,685
Pension and deferred compensation$0
All other$24,611
Total$2,364,380

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CG Oncology, Inc. DEF 14A filed April 24, 2026, accession 0001193125-26-177395, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CG Oncology, Inc. filed document, accession 0001193125-26-177395. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
Option62,500—$28.01
Option33,841—$36.63
Option99,935—$20.11

Per the Outstanding Equity Awards at Fiscal Year-End table in CG Oncology, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

CG Oncology’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Arthur KuanChairman and Chief Executive Officer$11,928,401
Ambaw BelletePresident and Chief Operating Officer$4,815,391
Vijay KasturiChief Medical Officer$3,599,947
Joshua Patterson · this pageGeneral Counsel, Chief Compliance Officer, and Secretary$2,364,380
Corleen RochePrior Chief Financial Officer$2,322,299
Robert LapetinaPrior Interim Principal Financial and Accounting Officer$645,297
Jim DeToreChief Financial Officer$96,000

Joshua Patterson's compensation dossier, CG Oncology

You have read Joshua Patterson's totals and holdings. The dossier adds each equity grant CG Oncology disclosed for Joshua Patterson and CG Oncology's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.

See an example →

The full CG Oncology compensation record

free company brief

This page is one person within CG Oncology's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CG Oncology's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CG Oncology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order CGON

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Joshua Patterson's compensation dossier